NEW
YORK, June 21, 2024 /PRNewswire/ -- The
global hospital infection therapeutics market size is
estimated to grow by USD
3.46 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 5.27%
during the forecast period. Increase in incidence and prevalence of
respiratory disorders is driving market growth, with a
trend towards increasing hospital visits.
However, stringent regulations poses a challenge. Key
market players include Abbott Laboratories, AbbVie Inc., Achilles
Therapeutics plc, AstraZeneca Plc, Basilea Pharmaceutica Ltd.,
Bayer AG, Bristol Myers Squibb Co., Cipla Inc., F. Hoffmann La
Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and
Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer
Inc., Sanofi SA, Spero Therapeutics Inc., Sun Pharmaceutical
Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris
Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Hospital Infection
Therapeutics Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
5.27%
|
Market growth
2024-2028
|
USD 3466.6
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
4.91
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
33%
|
Key
countries
|
US, Germany, China,
France, and UK
|
Key companies
profiled
|
Abbott Laboratories,
AbbVie Inc., Achilles Therapeutics plc, AstraZeneca Plc, Basilea
Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Co., Cipla Inc.,
F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline
Plc, Johnson and Johnson Services Inc., Merck and Co. Inc.,
Novartis AG, Pfizer Inc., Sanofi SA, Spero Therapeutics Inc., Sun
Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries
Ltd., and Viatris Inc.
|
Market Driver
The global hospital infection therapeutics market is projected
to expand due to the rising prevalence of chronic diseases and the
increasing number of patient visits to hospitals. Central venous
catheters, a leading cause of hospital-acquired infections (HAIs),
are estimated to increase by 8% by 2025. Intensive care units, with
their high susceptibility to infections, are a significant source
of these diseases. Sepsis, a common complication of hospital
infections, is a leading cause of death in the US and Australia, with over 600 and 1,500 fatalities
daily, respectively. The economic burden of hospital infection
diseases exceeds USD17 billion in the
US and is a significant concern in other countries. The aging
population, particularly in Japan,
the UK, the US, and Germany, is
more susceptible to infections and is expected to increase by 8-10%
by 2030, driving the demand for blood culture tests and market
growth.
The Hospital Infection Therapeutics market is experiencing
significant growth due to the increasing demand for effective
solutions to combat hospital-acquired infections. Environments such
as intensive care units and surgery centers pose a high risk for
infection transmission. Adopting technologies like urbanization,
construct technology, and engineering are crucial in creating
infection-resistant environments. Products like antimicrobial
coatings and disinfectants play a vital role in this market.
Infectence and Carbon are some companies providing innovative
solutions. The use of infusion technologies and ventilator systems
also contributes to infection control. Electronics and sensors are
essential tools for monitoring infection rates and ensuring proper
disinfection procedures. Renewable and sustainable technologies,
such as UV light disinfection, are gaining popularity due to their
eco-friendly nature and effectiveness against a wide range of
microorganisms. The market is expected to continue growing as
healthcare providers prioritize patient safety and infection
control. The integration of technology and innovation will further
drive market expansion.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The hospital infection therapeutics market faces regulatory
hurdles, with stringent FDA and EMA requirements for new drug
applications (NDAs). Applicants must provide extensive data on
preclinical studies, pharmacodynamic and pharmacokinetic
properties, safety profiles, dosage forms, mechanisms of action,
and routes of administration. Failure to meet these criteria can
result in complete response letters or rejections, necessitating
additional clinical trials and increased R&D expenditures. The
complex regulatory process, particularly for targeted therapies,
can negatively impact drug development and approval, limiting
market growth. Only about one in 5,000 new drugs reach the market,
with the FDA increasing regulatory scrutiny of cancer drugs. These
stringent regulations deter new entrants and challenge market
expansion during the forecast period.
- The Hospital Infection Therapeutics Market faces several
challenges in providing effective solutions. These include the
emergence of antibiotic-resistant bacteria, the need for new and
innovative treatments, and the high cost of developing and
implementing new technologies. Additionally, the complexity of
hospital environments and the need for continuous monitoring and
improvement of infection control practices add to the challenges.
Furthermore, the increasing incidence of infections and the
resulting healthcare costs pose a significant threat to both
patients and healthcare providers. To address these challenges,
there is a growing focus on the development of new antimicrobial
agents, the use of advanced technologies such as urbanization and
artificial intelligence, and the implementation of strict infection
control protocols.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This hospital infection therapeutics market report extensively
covers market segmentation by
- Drug Class
- 1.1 Antibiotics drugs
- 1.2 Antifungal drugs
- 1.3 Antiviral drugs
- Type
- 2.1 Respiratory tract infections
- 2.2 Surgical site infections
- 2.3 Bloodstream infections
- 2.4 Gastrointestinal infections
- 2.5 Urinary tract infections
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Antibiotics drugs- The global hospital
infection therapeutics market is driven by the increasing
prevalence of bacterial infections. Broad-spectrum antibiotics,
effective against various microorganisms, are crucial in severe
cases or when bacterial identification is difficult. Commonly used
broad-spectrum antibiotics include amoxicillin, levofloxacin, and
streptomycin. Narrow-spectrum antibiotics, active against specific
bacteria, are employed when the causative organism is identified.
Azithromycin, clarithromycin, and clindamycin are common examples.
Antibiotics are administered intravenously in severe cases and
orally in most instances. Oral forms include solutions,
suspensions, syrups, powders, and tablets. These factors contribute
significantly to the growth of the antibiotic drug segment in the
hospital infection therapeutics market.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2017-2021) - Download a Sample Report
Research Analysis
The Hospital Infection Therapeutics Market encompasses the
development, production, and distribution of advanced solutions
aimed at preventing and treating Ventilator-associated pneumonia
(VAP), Nosocomially acquired infections, and Healthcare-associated
infections (HAIs). With the growing concern over Antimicrobial
resistance, there is a pressing need for sustainable and
eco-friendly alternatives. High initial investment in electronics
and construction of advanced therapeutic devices can be offset by
Economies of Scale and the adoption of Renewable solutions.
Incentives from governments and organizations play a crucial role
in the market's growth. Product quality and Urbanization are
essential factors driving the demand for effective infection
therapeutics. Carbon emissions from traditional methods necessitate
the shift towards Eco-friendly and Sustainable practices. The
market's future lies in the integration of Environmental
consciousness, Cost reduction, and Incentives to ensure the
long-term sustainability of healthcare systems.
Market Research Overview
The Hospital Infection Therapeutics Market encompasses a range
of products and services designed to prevent and treat infections
contracted in healthcare settings. These include antimicrobial
agents, vaccines, diagnostic tools, and other therapeutic
interventions. The market is driven by the increasing prevalence of
hospital-acquired infections (HAIs), which pose significant health
risks and financial burdens to healthcare systems and patients. The
global market for Hospital Infection Therapeutics is expected to
grow steadily due to the rising demand for effective solutions to
combat HAIs, as well as advancements in technology and research.
Key factors influencing market growth include an aging population,
increasing healthcare expenditures, and the growing prevalence of
antibiotic-resistant bacteria. The market is segmented by product
type, application, and end user.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Drug Class
-
- Antibiotics Drugs
- Antifungal Drugs
- Antiviral Drugs
- Type
-
- Respiratory Tract Infections
- Surgical Site Infections
- Bloodstream Infections
- Gastrointestinal Infections
- Urinary Tract Infections
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hospital-infection-therapeutics-market-size-is-set-to-grow-by-usd-3-46-billion-from-2024-2028--increase-in-incidence-and-prevalence-of-respiratory-disorders-boost-the-market-technavio-302177964.html
SOURCE Technavio